Analytical Data
-
Gene name
ABCC8
- Application
-
Alternative Names
ABC-C8; PHHI; MRP8; ABC36; HHF1; HI; HRINS; SUR; SUR1; TNDM2; Sulfonylurea Receptor(Hyperinsulinemia)
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q09428
-
Expression Region
Val679~Thr929
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ABCC8, also known as the sulfonylurea receptor 1 (SUR1), plays a critical role in regulating insulin secretion from pancreatic beta cells. Mutations in the ABCC8 gene are associated with various forms of congenital hyperinsulinism (CHI) and diabetes mellitus, making it a key target for understanding and treating these conditions. The protein is part of the ATP-sensitive potassium (KATP) channel complex, which modulates the cellular excitability of beta cells in response to metabolic changes. Research into recombinant forms of ABCC8 has gained momentum as scientists seek to elucidate its structure and function, providing insights into the mechanisms governing insulin release and potential therapeutic interventions. By producing and characterizing ABCC8 recombinant proteins, researchers aim to investigate its interactions with ATP, sulfonylureas, and other cellular components, paving the way for novel treatments for hyperinsulinism and diabetes. Additionally, these studies may help in the design of targeted drugs that can modulate KATP channel activity, enhancing our understanding of glucose homeostasis and potential metabolic disorders. Overall, the exploration of ABCC8 recombinant proteins serves as a foundation for advancing both basic science and clinical applications in endocrinology and metabolic disease management.
